Hardman Johnston Large Cap Equity has maintained its significant stake in IQVIA Holdings Inc. (IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The investment firm's position was confirmed in portfolio disclosures for the second quarter of 2026. This continued backing comes as the broader Contract Research Organization (CRO) sector demonstrates resilience amid evolving pharmaceutical R&D spending, with the global CRO market size estimated at approximately $89 billion.
Context — why this matters now
Institutional confidence in the CRO sector is a key indicator of expected pharmaceutical and biotech research and development cycles. The last major inflection point for CRO stocks occurred during the pandemic, when IQVIA's share price increased over 60% from pre-pandemic levels to a peak in late 2021, driven by urgent vaccine and therapeutic development. The current macro backdrop features sustained, though moderated, R&D budgets from large-cap pharma, with the 10-year Treasury yield at 4.2% influencing the discount rates used in valuing long-duration growth assets like CROs.
The catalyst for reaffirming the IQVIA position is the accelerating trend of outsourcing within biopharma. Companies are increasingly focusing capital on core discovery and marketing, shifting the complex, capital-intensive work of clinical trial management to specialized partners. This structural shift provides a multi-year tailwind for established players with global scale and data assets. IQVIA's proprietary anonymized patient data sets, which cover over one billion patient records, create a significant competitive moat that is difficult for new entrants to replicate.
Data — what the numbers show
IQVIA reported first-quarter 2026 revenue of $4.1 billion, a 5.5% year-over-year increase. The company's Research & Development Solutions (R&D) segment, its core CRO business, contributed $2.7 billion of that total. IQVIA's backlog reached a record $30.2 billion, providing visibility into future revenue streams. The stock has gained 18% year-to-date, outperforming the S&P 500's 8% return over the same period.
IQVIA's financial metrics demonstrate its operational strength. The company's market capitalization stands at approximately $48 billion. Its net debt to adjusted EBITDA ratio was maintained at 3.2x, within its target range. IQVIA's peer, Labcorp's clinical development unit, reported a 3.7% organic growth rate in its latest quarter, while Charles River Laboratories saw its research models services segment decline by 4%.
| Metric | Q1 2026 | Q1 2025 | Change |
|---|
| Revenue | $4.1B | $3.89B | +5.5% |
| R&D Solutions Revenue | $2.7B | $2.55B | +5.9% |
| Backlog | $30.2B | $28.5B | +6.0% |
Analysis — what it means for markets / sectors / tickers
Hardman Johnston's stance signals confidence that large-cap CROs like IQVIA are well-positioned to capture a greater share of the expanding biopharma R&D pie. This is a positive read-across for other major CROs, including Labcorp (LH) and Thermo Fisher's clinical research division. Providers of clinical trial technology, such as Medpace (MEDP) and Veeva Systems (VEEV), may also see increased demand as trial complexity grows. Conversely, smaller, less-diversified CROs face margin pressure from rising labor costs and competition for specialized clinical talent.
A key risk to the thesis is potential consolidation among large pharmaceutical companies, which could lead to R&D budget rationalization and temporary delays in outsourcing decisions. Geopolitical tensions also present a risk, as a significant portion of clinical trials are conducted internationally, exposing CROs to currency and regulatory volatility. Despite these risks, institutional flow data indicates continued net buying interest in the healthcare services sector, with a focus on companies demonstrating pricing power and recurring revenue models.
Outlook — what to watch next
IQVIA is scheduled to report its second-quarter 2026 earnings on July 24, 2026. Analysts will scrutinize the net book-to-bill ratio for the R&D Solutions segment for signs of demand sustainability. Any figure consistently above 1.2x would signal strong future growth. The next major industry conference, the J.P. Morgan Healthcare Conference in January 2027, will provide guidance from a broad range of biopharma clients on their 2027 R&D budgets.
Technically, IQV shares are approaching a key resistance level near $265, which has capped advances twice in the past 18 months. A sustained breakout above this level on high volume would be a technically bullish signal. Support is seen near the 200-day moving average, currently around $235. The 10-year Treasury yield remains a critical macro variable; a significant move above 4.5% could pressure the valuations of all long-duration growth stocks, including CROs.
Frequently Asked Questions
What is a CRO in the pharmaceutical industry?
A Contract Research Organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of outsourced research services. These services are predominantly related to the management and execution of clinical trials, which are necessary for gaining regulatory approval for new drugs. CROs like IQVIA handle patient recruitment, data management, regulatory compliance, and statistical analysis, allowing drug developers to operate more efficiently and accelerate time-to-market for new therapies. The global CRO market has grown significantly as outsourcing has become a standard industry practice.
How does IQVIA differ from its competitors?
IQVIA distinguishes itself through the integration of its massive healthcare data assets with its traditional CRO services. The company's Real-World Solutions segment leverages anonymized data from over one billion patient records, which provides unique insights into treatment patterns and patient outcomes. This data advantage allows IQVIA to help clients design more effective clinical trials and supports advanced analytics services post-drug approval. While competitors like Labcorp and PPD (owned by Thermo Fisher) are strong in trial execution, IQVIA's combination of data, analytics, and operational scale creates a differentiated offering that is particularly valuable for large, complex studies.
What are the primary risks to investing in the CRO sector?
The CRO sector faces several inherent risks. Clinical trial delays or failures for a sponsor's drug candidate can lead to reduced revenue for the CRO, even though they are typically paid for services rendered regardless of trial outcome. A downturn in biotech funding can immediately impact R&D budgets and new project awards, as smaller biotech firms are a key client segment. Regulatory changes, such as stricter clinical trial guidelines from the FDA or EMA, can increase operational costs. Finally, intense competition for skilled clinical research associates and data managers can lead to wage inflation, compressing profit margins across the industry.
Bottom Line
Hardman Johnston's sustained IQVIA stake reflects a conviction in the structural growth of clinical trial outsourcing.
